{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:04:36Z","timestamp":1780031076577,"version":"3.53.1"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"South African National Research Foundation","award":["121278"],"award-info":[{"award-number":["121278"]}]},{"name":"NIH","award":["01AI154659"],"award-info":[{"award-number":["01AI154659"]}]},{"name":"NIH","award":["R01AI152183"],"award-info":[{"award-number":["R01AI152183"]}]},{"name":"NIH","award":["R01HG010863"],"award-info":[{"award-number":["R01HG010863"]}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Allergy and Infectious Diseases of the National Institutes of Health","award":["R01AI152183"],"award-info":[{"award-number":["R01AI152183"]}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["TMA2017SF-1981"],"award-info":[{"award-number":["TMA2017SF-1981"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Research Foundation (NRF) SARChI Chair in Dermatology and Toxicology grant"},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Severe cutaneous adverse drug reactions (SCARs) are associated with mental health sequelae and reduced quality of life. However, existing research is limited by small retrospective cohorts, overrepresentation of high-income countries, lighter skin tones, inadequate controls, and a paucity of prospective longitudinal case-control studies assessing the psychological sequelae in SCAR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to prospectively determine and compare the longitudinal trajectories of psychological sequelae in patients with SCAR and controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Between June 2020 and October 2023, SCAR cases and matched controls were recruited. The following validated instruments were used for assessments: (1) the MINI International Neuropsychiatric Interview to assess depression and suicide risk; (2) the Kessler Psychological Distress Scale (K10) to determine pre-existing depression; (3) the Cutaneous Body Image (CBI) scale to measure self-perception of body image; and (4) the Dermatology quality life index (DQLI) to measure the impact of SCAR on health-related quality of life (QoL). Assessments were conducted at admission (baseline or\n                      <jats:italic>t<\/jats:italic>\n                      <jats:sub>0<\/jats:sub>\n                      ), 6\u202fmonths (\n                      <jats:italic>t<\/jats:italic>\n                      <jats:sub>1<\/jats:sub>\n                      ), and 12\u202fmonths (\n                      <jats:italic>t<\/jats:italic>\n                      <jats:sub>2<\/jats:sub>\n                      ) after the development of SCARs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Total of 47 SCAR cases (8 SJS\/TEN, 35 DRESS, and 4 GBFDE) and 30 controls were recruited. All had Fitzpatrick skin types \u2265III. Cases had significantly higher prevalence of depression [21\/47 (45%) vs. 4\/30 (13.3\u2032%),\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.006] and suicide risk [12\/21 (57%) vs. 1\/4 (25%),\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.012] compared to controls at\n                      <jats:italic>t<\/jats:italic>\n                      <jats:sub>0.<\/jats:sub>\n                      This was maintained at\n                      <jats:italic>t<\/jats:italic>\n                      <jats:sub>1<\/jats:sub>\n                      and\n                      <jats:italic>t<\/jats:italic>\n                      <jats:sub>2<\/jats:sub>\n                      . Of 45 cases, 36 (80%) had severe negative self-perception, significantly more than in controls [10\/18 (56%),\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.023] at\n                      <jats:italic>t<\/jats:italic>\n                      <jats:sub>0<\/jats:sub>\n                      . Among the cases, 20% continued to experience this negative self-perception, while 9% experienced a deterioration over time. Only one showed persistent negative self-perception among controls. At\n                      <jats:italic>t<\/jats:italic>\n                      <jats:sub>0,<\/jats:sub>\n                      cases had significantly impaired QoL compared to controls\n                      <jats:sub>,<\/jats:sub>\n                      with a median (IQR) DLQI score of [9.3 (4\u201315) vs. 1.5 (0\u20133),\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001]. However, this effect was lost over time. A major limitation of the study was the high rate of loss-to-follow-up due to coronavirus disease 2019 (COVID-19).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SCARs were found to be associated with a high risk of depression, suicide, impaired QoL, and severe negative self-perception compared to controls. SCAR patients demonstrated persistent or worsening impairments at 6\u202fmonths and relapses at 12\u202fmonths. These findings highlight the ongoing psychosocial burden of SCARs and the need for integrated mental health support.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1774494","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:44:32Z","timestamp":1780029872000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective longitudinal study of psychological sequelae, self-perception of body image, and quality of life in severe cutaneous adverse drug reactions: a case-control study"],"prefix":"10.3389","volume":"13","author":[{"given":"Eddy M.","family":"Zitha","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneliswa","family":"Mpungose","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovemore","family":"Mapahla","sequence":"additional","affiliation":[{"name":"The Modelling and Simulation Hub, Africa, Department of Statistical Sciences, University of Cape Town","place":["Cape Town, South Africa"]},{"name":"The Division of Epidemiology & Biostatistics, Faculty of Medicine and Health Sciences, Stellenbosch University","place":["Cape Town, South Africa"]},{"name":"Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avumile","family":"Mankahla","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine and Pharmacology, Nelson Mandela Academic Hospital, Walter Sisulu University","place":["Mthatha, Eastern Cape, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bukiwe","family":"Thwala","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Porter","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Abrahams","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuti","family":"Choshi","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Hoenck","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhodine","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pirjol","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sipho","family":"Dlamini","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and HIV Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Phillips","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonny","family":"Peter","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rannakoe J.","family":"Lehloenya","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bcp.15645","article-title":"Report of a WHO meeting","volume":"498","year":"1972","journal-title":"World Health Organ Tech Rep Ser"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1111\/bcp.15645","article-title":"Pathophysiology of drug hypersensitivity","volume":"90","author":"Elzagallaai","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","volume":"43","author":"Chung","year":"2016","journal-title":"J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice","volume":"5","author":"Peter","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.12659\/MSM.904682","article-title":"Adverse events associated with treatment of multidrug-resistant tuberculosis in China: an Ambispective cohort study","volume":"23","author":"Zhang","year":"2017","journal-title":"Med Sci Monit"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/ACI.0000000000000545","article-title":"Drug hypersensitivity in HIV infection","volume":"19","author":"Peter","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/pds.4067","article-title":"Severe antiretroviral-associated skin reactions in south African patients: a case series and case-control analysis","volume":"25","author":"Stewart","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.jaip.2018.10.053","article-title":"Lower-than-predicted mortality in a predominantly HIV-infected population with epidermal necrolysis regardless of HIV status: implications and challenges for interventional studies","volume":"7","author":"Lehloenya","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.seizure.2021.07.011","article-title":"Severe cutaneous adverse reactions in Asians: trends observed in culprit anti-seizure medicines using VigiBase\u00ae","volume":"91","author":"Shukla","year":"2021","journal-title":"Seizure"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jaip.2020.09.011","article-title":"A Nationwide study of severe cutaneous adverse reactions based on the multicenter registry in Korea","volume":"9","author":"Kang","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"652091","DOI":"10.3389\/fmed.2021.652091","article-title":"Genetics of severe cutaneous adverse reactions","volume":"8","author":"Yang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"644154","DOI":"10.3389\/fmed.2021.644154","article-title":"Implementation of Pharmacogenomic information on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"8","author":"Tsukagoshi","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1586\/eri.12.13","article-title":"Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future","volume":"10","author":"Lehloenya","year":"2012","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.2174\/1381612825666191107162921","article-title":"Clinical phenotypes of severe cutaneous drug hypersensitivity reactions","volume":"25","author":"Guvenir","year":"2019","journal-title":"Curr Pharm Des"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.02.003","article-title":"SJS\/TEN 2019: from science to translation","volume":"98","author":"Chang","year":"2020","journal-title":"J Dermatol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/bjd.12133","article-title":"Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"168","author":"Lipowicz","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2050313x241307117","DOI":"10.1177\/2050313X241307117","article-title":"Clinical cues for distinguishing bullous fixed drug eruption from Stevens-Johnson syndrome: a case report","volume":"12","author":"Samman","year":"2024","journal-title":"SAGE Open Med Case Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/medicina57090925","article-title":"A review of fixed drug eruption with a special focus on generalized bullous fixed drug eruption","volume":"57","author":"Anderson","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis","volume":"10","author":"Hama","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1111\/all.13440","article-title":"Multiple drug intolerance syndrome and multiple drug allergy syndrome: epidemiology and associations with anxiety and depression","volume":"73","author":"Blumenthal","year":"2018","journal-title":"Allergy"},{"key":"ref25","volume-title":"Prevalence of Anxiety and depression in a Predominantly HIV-Infected Population with Severe Cutaneous Adverse Drug Reactions [Dissertation]","author":"Zitha","year":"2016"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdin.2020.12.004","article-title":"Acute generalized exanthematous pustulosis: epidemiology, clinical course, and treatment outcomes of patients treated in an Asian academic medical center","volume":"3","author":"Oh","year":"2021","journal-title":"JAAD Int"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1440-0960.2011.00845.x","article-title":"Acute generalised exanthematous pustulosis","volume":"53","author":"Fernando","year":"2012","journal-title":"Australas J Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/bjd.12502","article-title":"Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients","volume":"169","author":"Hotz","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"832048","DOI":"10.3389\/fphar.2022.832048","article-title":"Drug-induced severe cutaneous adverse reactions: insights into clinical presentation, Immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics","volume":"13","author":"Tempark","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jaad.2015.07.017","article-title":"Acute generalized exanthematous pustulosis (AGEP): a review and update","volume":"73","author":"Szatkowski","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1001\/jamadermatol.2021.1136","article-title":"Long-term physical and psychological outcomes of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"157","author":"Hoffman","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/bjd.13375","article-title":"Post-traumatic stress disorder following drug reaction with eosinophilia and systemic symptoms","volume":"172","author":"Lew","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/bjd.18746","article-title":"The psychological impact of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis on patients' lives: a critically appraised topic","volume":"183","author":"O'Reilly","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2340\/00015555-2295","article-title":"Long-term sequelae of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"96","author":"Yang","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/bjd.14831","article-title":"Psychological sequelae of toxic epidermal necrolysis: further insights","volume":"175","author":"Walsh","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/bjd.14799","article-title":"Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"175","author":"Dodiuk-Gad","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref38","volume-title":"IMmune-mediated adverse drug reactions in African HIV endemic setting (IMARI-SA study)","author":"Peter","year":"2018"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jaad.2013.11.053","article-title":"Comments on: DRESS syndrome","volume":"71","author":"Kardaun","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"ref42","first-page":"22","article-title":"The Mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1017\/S0033291702006074","article-title":"Short screening scales to monitor population prevalences and trends in non-specific psychological distress","volume":"32","author":"Kessler","year":"2002","journal-title":"Psychol Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/archpsyc.60.2.184","article-title":"Screening for serious mental illness in the general population","volume":"60","author":"Kessler","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.0022-202X.2004.23214.x","article-title":"Cutaneous body image: empirical validation of a dermatologic construct","volume":"123","author":"Gupta","year":"2004","journal-title":"J Invest Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1346-8138.2009.00690.x","article-title":"Japanese version of cutaneous body image scale: translation and validation","volume":"36","author":"Higaki","year":"2009","journal-title":"J Dermatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1016\/j.jaip.2025.08.001","article-title":"HLA-B Alleles with Shared Peptide Binding Specificities Define Global Risk of Cotrimoxazole-Induced SCAR","volume":"13","author":"Li","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"661135","DOI":"10.3389\/fimmu.2021.661135","article-title":"HLA-B*13:01 is a predictive marker of Dapsone-induced severe cutaneous adverse reactions in Thai patients","volume":"12","author":"Satapornpong","year":"2021","journal-title":"Front Immunol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fphar.2020.00078","article-title":"Genetic diversity of HLA class I and class II alleles in Thai populations: contribution to genotype-guided therapeutics","volume":"11","author":"Satapornpong","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fphar.2016.00186","article-title":"HLA-B (*) 58:01 for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in Thailand","volume":"7","author":"Sukasem","year":"2016","journal-title":"Front Pharmacol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/1346-8138.16487","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis associated with increased risk of developing psychiatric disorders: a retrospective population-based cohort study in Taiwan","volume":"49","author":"Chiang","year":"2022","journal-title":"J Dermatol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jdin.2024.07.027","article-title":"Patients with severe cutaneous adverse drug reactions have extremely high hair cortisol concentrations that do not correlate with presence of depression. [unpublished manuscript]","volume":"17","author":"Zitha","year":"2023","journal-title":"JAAD Int"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/bjd\/ljae334","article-title":"The quality-of-life impact of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) on patients' lives: an interpretative descriptive qualitative study","volume":"192","author":"O'Reilly","year":"2024","journal-title":"Br J Dermatol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13023-023-02631-7","article-title":"Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus","volume":"18","author":"Ingen-Housz-Oro","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/bjd\/ljaf229","article-title":"Impact of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) on the health-related quality of life (HRQoL) experiences of adults with SJS\/TEN: a mixed-methods systematic review","volume":"193","author":"O'Reilly","year":"2025","journal-title":"Br J Dermatol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","article-title":"Severe cutaneous adverse reactions","volume":"10","author":"Hung","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ejim.2003.09.004","article-title":"DRESS syndrome associated with HHV-6 reactivation","volume":"14","author":"Ichiche","year":"2003","journal-title":"Eur J Intern Med"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"46ra62","DOI":"10.1126\/scitranslmed.3001116","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response","volume":"2","author":"Picard","year":"2010","journal-title":"Sci Transl Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1542\/peds.2010-3322","article-title":"Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children","volume":"128","author":"Finkelstein","year":"2011","journal-title":"Pediatrics"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1774494\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:44:54Z","timestamp":1780029894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1774494\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":59,"alternative-id":["10.3389\/fmed.2026.1774494"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1774494","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1774494"}}